CN Patent

CN107400134A — 嘌呤衍生物的结晶形式

Assigned to Cyclacel Ltd · Expires 2017-11-28 · 8y expired

What this patent protects

本发明涉及显示出优异抗肿瘤活性的嘌呤衍生物的新的结晶形式。本发明也涉及包含所述结晶形式作为活性成分的药物组合物，及其用于预防或治疗疾病的用途。本发明进一步涉及制备所述结晶形式的方法。

USPTO Abstract

本发明涉及显示出优异抗肿瘤活性的嘌呤衍生物的新的结晶形式。本发明也涉及包含所述结晶形式作为活性成分的药物组合物，及其用于预防或治疗疾病的用途。本发明进一步涉及制备所述结晶形式的方法。

Drugs covered by this patent

rolapitant-hydrochloride (ROLAPITANT HYDROCHLORIDE)

Patent Metadata

Patent number: CN107400134A
Jurisdiction: CN
Classification: —
Expires: 2017-11-28
Drug substance claim: No
Drug product claim: No
Assignee: Cyclacel Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.